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LETTERS TO THE EDITORS—RESEARCH REPORTS

Low Incidence of Neuroleptic
Malignant Syndrome
Associated With Paliperidone
Palmitate Long-Acting
Injectable
A Database Report and
Case Study

To the Editors:
euroleptic malignant syndrome (NMS)
is a rare, potentially fatal, and idiosyncratic adverse reaction that occurs in approximately 0% to 3% of individuals taking
conventional antipsychotic medication.1–4
This syndrome usually presents with rigidity, abrupt onset of fever, autonomic dysregulation, and altered mental status.1 Other
symptoms associated with NMS include
tremor, extrapyramidal symptoms, altered
electrocardiogram, and laboratory abnormalities, such as elevated serum creatine
kinase (CK), impaired liver function tests,
leukocytosis, electrolyte abnormalities, renal impairment, and altered coagulation
(Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition criteria for NMS).
The primary cause of NMS is thought to be
dopamine receptor blockade, particularly with
the use of antipsychotic medications.5
Available evidence of NMS associated
with oral antipsychotics suggests that second-generation oral antipsychotics have a
lower incidence of NMS, with less severity
and infrequent fatal outcomes, compared
with first-generation oral antipsychotics.6–9
In contrast, little is known about the frequency and management of NMS associated with long-acting injectables (LAIs)
prescribed for treatment of schizophrenia,
including LAIs of paliperidone (9-OH metabolite of risperidone) such as paliperidone
palmitate 1-monthly (PP1M) and 3-monthly
(PP3M). The concern about NMS development due to LAI antipsychotics and the
associated hospitalization, morbidity, and
mortality limits LAI usage in clinical practice in the United States. Also, LAIs may
be underutilized because of the perception
that an LAI antipsychotic is not quickly
cleared from the patient's system and may
hinder NMS management. This letter discusses the incidence and nature of NMS
associated with paliperidone palmitate
LAI formulations identified from Janssen
clinical trial databases of PP1M and PP3M
and the treatment implications for NMS
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associated with second-generation antipsychotic LAI formulations.
All cases of NMS in the Janssen
PP1M and PP3M phases 1 to 3 clinical trial
databases were searched cumulatively through
April 30, 2018. Specific Medical Dictionary
for Regulatory Activities (MedDRA, version
16.0) preferred terms used in the search for
NMS are listed in Table 1. Individual case review was performed for each patient who
experienced at least one of the terms
listed. In each identified case, reports of
treatment-emergent adverse events, vital
signs, physical examination, laboratory
findings, and clinical management of
the event were reviewed. The incidence rate
of NMS was calculated based on the number

of identified cases divided by the total person-time at risk.
The Janssen clinical trial database
search identified 1 credible case of NMS
from 5008 patients who received 1 or more
injection of PP1M or PP3M and were
followed for 2271.6 patient-years. A second case of NMS was identified but was not
included in this study because the patient (from a single-dose pharmacokinetics
study in Japan; NCT01606254) was diagnosed with NMS more than 3 months (approximately 3 half-lives) after the last
injection of PP1M. Furthermore, the patient
was receiving other antipsychotics at the
time of diagnosis of NMS. The resulting
raw incidence of NMS was 0.020% (95%

TABLE 1. List of Preferred Terms Used in the Search for NMS in the Janssen Clinical
Trial Database
Hyperthermia malignant
NMS
Serotonin syndrome
Body temperature increased
Hyperpyrexia
Pyrexia
Catatonia
Dyskinesia
Dystonia
Freezing phenomenon
Hyperkinesia
Hypertonia
Muscle necrosis
Muscle rigidity
Oculogyric crisis
Oculogyration
Opisthotonus
Rhabdomyolysis
Altered state of consciousness
Autonomic nervous system imbalance
Blood creatine phosphokinase abnormal
Blood creatine phosphokinase increased
Blood creatine phosphokinase MM increased
Blood pressure abnormal
Blood pressure decreased
Blood pressure fluctuation
Blood pressure increased
Cardiovascular insufficiency
Coma
Confusional state
Consciousness fluctuating

Delirium
Depressed level of consciousness
Disorientation
Extrapyramidal disorder
Heart rate abnormal
Heart rate increased
Hyperhidrosis
Hypertension
Hypotension
Labile blood pressure
Labile hypertension
Leukocytosis
Loss of consciousness
Muscle enzyme increased
Myoclonus
Myoglobin blood increased
Myoglobin blood present
Myoglobin urine present
Myoglobinemia
Myoglobinuria
Parkinsonian crisis
Parkinsonian rest tremor
Parkinsonism
Parkinson's disease
Stupor
Tachycardia
Tremor
Unresponsive to stimuli
White blood cell count abnormal
White blood cell count increased

Preferred terms used were from Medical Dictionary for Regulatory Activities (MedDRA,
version 16.0).
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confidence interval, 0.0028%–0.14%), and
the incidence rate was 0.044% (95% confidence interval, 0.042%–0.13%) per year.

CASE REPORT
The patient identified with NMS was a
55-year-old, white man with a diagnosis
of schizophrenia, paranoid type, since 17 years
of age who was enrolled in a randomized,
double-blind, parallel-group study of flexibly dosed PP1M versus Risperdal CONSTA
(Risperidone LAI).10 The patient had 4 prior
hospitalizations for psychosis and a history
of smoking, had no alcohol or drug abuse,
and had no other significant medical history reported. The physical examination at
screening was unremarkable, except for reduced hearing in the left ear, cerumen in
both ear canals, gum disease, cavities, and
a body mass index of 25.7 kg/m2 (overweight). The patient was previously treated
with flupenthixol decanoate 15 mg intramuscularly every 2 weeks for 6 years,
which was discontinued 22 days prior to
randomization. From day −6 to day −3 of
the screening period, the patient was given
paliperidone extended release 3 mg for oral
tolerability testing. On days 1 and 8 of the
double-blind period, the patient received
an injection of 50 mg eq PP1M in the
gluteal muscle. A predose pharmacokinetic plasma sample was collected on
day 1, and paliperidone levels were below
the limit of quantification.
On day 15, the patient was hospitalized for confused mental state and had
experienced a fever (38.8°C) and little
rigidity and had “trouble relaxing” his
muscles. The diagnosis of mild NMS was
made, and laboratory results showed elevated levels of CK (5824 U/L [reference
range, 55–197 U/L]) and hepatic enzymes,
including aspartate transaminase (128 U/L
[reference range, 12–45 U/L]) and alanine
transaminase (91 U/L [reference range,
7–40 U/L]). Blood pressure and pulse rate
were normal.
On day 16, lorazepam 0.5 to 1 mg/d as
a rescue medication was initiated and continued as needed for 2 days, and ciprofloxacin 500 mg twice daily for 6 days was given
for suspected infection that was later
ruled out. Treatment with PP1M was
discontinued on day 19 (last dose was on
day 8), and the patient was withdrawn from
the study because of the serious treatmentemergent adverse event of NMS. On
day 20, the CK level was 860 U/L, alanine
transaminase was 52 U/L, and aspartate
transaminase was 49 U/L. Benztropine 1
to 2 mg/d was given from days 19 to 26,
then the dose was tapered and discontinued
over 2 days. Flupenthixol decanoate 15 mg
intramuscularly every 2 weeks was resumed
on day 23. The pyrexia was treated with

acetaminophen as needed. No additional
treatment was given for dizziness, psychotic
disorder, elevated liver enzymes, or elevated
CK levels. On day 28, the patient went on a
“leave of absence” from the hospital as he
was reported to have done reasonably well
but returned to the hospital on day 34 after
feeling unwell, with disorientation. The
patient had fever of 38.5°C on day 34, but
his temperature soon returned to normal
(patient's home was not air conditioned,
and the city of residence was warm at that
time). After all investigations were normal,
the patient went on a second leave of absence from days 36 to 46. The patient was
discharged from the hospital on day 46 following complete recovery.

DISCUSSION
From data of 5008 patients analyzed in the
Janssen clinical trial database for NMS
with PP1M and PP3M, a single case of
NMS associated with PP1M LAI was
identified. The most common manifestations of NMS, including altered mental
state, muscle rigidity, fever, and elevated
CK (>1000 U/L), were reported in this
case. The severity of NMS appeared to be
mild, and the patient recovered completely.
This database review illustrates the low
propensity for NMS events during PP1M
or PP3M treatment and successful
management of this complication in
the single case identified with symptomatic treatment.
Given that NMS is a known and rare
adverse event associated with use of antipsychotics, the investigator judged that
the etiology of NMS was possibly related
to PP1M. However, the patient was also
receiving flupenthixol decanoate 15 mg
intramuscularly every 2 weeks (variable
half-life between 3 weeks and 3 months)
for 6 years prior to randomization, which
was discontinued 22 days before PP1M
administration. Thus, it is possible that initiation of NMS on day 15 cannot be attributed solely to PP1M, but rather could be
related to a combined effect of both LAI
antipsychotic agents (flupenthixol decanoate
and PP1M). Also, worsening of symptoms
on day 34 could likely be related to the
flupenthixol depot given on day 23, further
supporting the additive effect of the 2 drugs.
Findings from a retrospective study also
showed that the use of depot flupenthixol
was significantly associated with increased risk of NMS.11 In the present case,
oral tolerability medication (paliperidone
extended release), although below limit of
quantification at baseline, may also be a
contributory factor.
Potential limitations of this study include possible underreporting of adverse
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drug reaction, inadequate sensitivity of the
search method, and relatively short follow-up
time of patients (on average, ~5.4 months).
In summary, based on the search
conducted in the Janssen clinical trial database, the occurrence of NMS events associated with PP1M or PP3M was very low
(4/10,000 patient-years); clinicians must,
however, be cautious to identify potential
NMS symptoms after administration of LAI
antipsychotics, especially when patients
have been recently taking long-acting firstgeneration antipsychotics. The presented
case indicates that NMS can be managed
symptomatically even when the patient is
on an LAI antipsychotic, and it underscores
the importance of early detection and pharmacological intervention in preventing the
progression of this potentially life-threatening
complication of antipsychotic use.
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Effects of Curcumin on
Cognitive Functioning and
Inflammatory State in
Schizophrenia
A Double-Blind,
Placebo-Controlled Pilot Trial
To the Editors:
urcumin, derived from turmeric root,
is a polyphenol with antioxidant and
anti-inflammatory properties.1,2 To our knowledge, only 2 studies have tested the effectiveness of add-on curcumin in patients with
schizophrenia.2,3 In an open-label study,
1 g/d of curcumin (n = 7) and 4 g/d of
curcumin (n = 8) improved overall neurocognitive index over 12 weeks. More recently,
a randomized, double blind, placebo-controlled
study showed that 360 mg/d of curcumin
(n = 17) increased brain-derived neurotrophic factor levels compared with placebo
(n = 19) after an 8-week trial. Although this
study did not show any significant changes
in clinical symptoms and cognitive functioning, improvement on brain-derived neurotrophic factor levels suggested possible
long-term benefits of curcumin in cognition and clinical symptoms.2
We tested the effects of add-on curcumin
for the treatment of cognitive impairment
in schizophrenia in an 8-week randomized,
double-blind, placebo-controlled, parallel,
fixed-dose pilot clinical trial. A total of 12
outpatients with schizophrenia were randomized to curcumin (180 mg/d) or placebo in a
1:1 ratio. Written informed consent was
obtained from all participants. A commercially
available surface-controlled water-soluble form
of 300 mg of curcumin (30% formulation:
90 mg pure curcumin) or matching placebo
capsules were provided by Theravalues

C

Corporation (Tokyo, Japan). Study protocol was approved by institutional review
board (Yale HIC number 1412015121)
and registered on ClinicalTrials.gov
(NCT02476708). We monitored medication adherence by means of pill count
method and patient reports.
The primary outcome measure was
between-group changes in Measurement and
Treatment Research to Improve Cognition
in Schizophrenia (MATRICS) Consensus
Cognitive Battery.4 Secondary outcomes included changes in inflammatory markers (interleukin 6 [IL-6], tumor necrosis factor α, and
high-sensitive C-reactive protein [hs-CRP]) and
clinical outcomes (Positive and Negative Symptom Scale [PANSS], Calgary Depression Scale
for Schizophrenia, and The Committee of Clinical Investigations (UKU) side effect scale).
All statistical analyses were performed
in SPSS Statistics version 24.0 (IBM, NY).
Baseline differences and treatment effect
in clinical symptoms, cognitive functioning,
and inflammatory markers were assessed
with nonparametric tests. Pearson χ2 analysis and Fisher exact tests were used for all
categorical variables.
The study sample (9 male, 3 female)
mostly consisted of chronic schizophrenia
patients with mean ± SD duration of illness
21.66 ± 14.84 years (range, 5–51 years).
Mean ± SD age of the total sample was
41.33 ± 12.73 years, and education level
was 12.33 ± 2.42 years. At baseline, no significant difference was found in sample
characteristics, inflammatory markers, and
clinical outcomes between treatment arms.
Table 1 summarizes changes in inflammatory markers, clinical outcomes, and cognitive functioning. Compared with placebo,
add-on curcumin treatment significantly
improved working memory (Z = 2.200,
P = 0.028) and reduced IL-6 levels
(Z = 2.402, P = 0.016). No significant effect of curcumin on PANSS and Calgary
Depression scores was found. No significant adverse events were reported during
the study. The majority of the patients reported that they took the medications as
prescribed. Only 2 patients returned 10
capsules in total during the whole study period (4 curcumin and 6 placebo capsules).
In this pilot study, we found that add-on
curcumin improved working memory in patients with schizophrenia. Add-on curcumin
also reduced IL-6 levels after 8 weeks of
treatment. Although improvements in other
cognitive domains, negative symptoms, and
total PANSS score were observed with addon curcumin, these changes did not reach
statistical significance.
To a degree, our findings are in line with
previous studies. In an open-label study,
Woodbury-Farina et al3 reported improvement in cognitive functioning and negative
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